
    
      This study is randomized, double-blinded, and placebo-controlled. 80 Patients will be
      enrolled and randomized to CSJ148 and placebo in a ratio of 3:1. Patients undergoing stem
      cell transplantation will be enrolled into the study. The study will consist of a screening
      period, a baseline visit, approximately 3-month treatment exposure period, an end-of-therapy
      visit, a follow-up period, and a study completion evaluation approximately 3.5 months after
      the last dose of study drug is administered.
    
  